Endogenous accumulation of IFN-? in IFN-?-R^{<bold>-/-</bold>} mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-? anti-tumor cytotoxicity in vitro and in vivo

References

• Fidler IJ, Selection of successive tumor lines for metastasis. Nat New Biol (1973) 242: 148–9.
   Google Scholar
• Overwijk WW, Tsung A, Irvine KR et al, gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 188: 277–86.
   Google Scholar
• Bowne WB, Srinivasan R, Wolchok JD et al, Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 190: 1717–22.
   Google Scholar
• Xu X, Azumi N, Skelton HG et al, Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen. Eur J Cancer (1996) 32A: 168–73.
   Google Scholar
• Naftzger C, Takechi Y, Kohda H et al, Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA (1996) 93: 14809–14.
   Google Scholar
• Weber LW, Bowne WB, Wolchok JD et al, Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 102: 1258–64.
   Google Scholar
• Hawkins WG, Gold JS, Blachere NE et al, Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res (2002) 102: 137–43.
   Google Scholar
• Lollini PL, Colombo MP, De Giovanni C et al, In vivo reexpression of H-2 antigens in B16 melanoma cells. Exp Clin Immunogenet (1985) 2: 14–23.
   Google Scholar
• Bohm W, Thoma S, Leithauser F et al, T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J Immunol (1998) 161: 897–908.
   Google Scholar
• Boehm U, Klamp T, Groot M, Howard JC, Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 15: 749–95.
   Google Scholar
• Billiau A, Heremans H, Vermeire K, Matthys P, Immunomodulatory properties of interferon-gamma. An update. Ann N Y Acad Sci (1998) 856: 22–32.
   PubMed Web of Science ®Google Scholar
• Hawley RG, Berger LC, Growth control mechanisms in multiple myeloma. Leuk Lymph (1998) 29: 465–75.
   Google Scholar
• Detjen KM, Kehrberger JP, Drost A et al, Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int J Oncol (2002) 21: 1133–40.
   Google Scholar
• Li JH, Kluger MS, Madge LA et al, Interferon-gamma augments CD95 (APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. Am J Pathol (1996) 161: 1485–95.
   Google Scholar
• Coughlin CM, Salhany KE, Gee MS et al, Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 9: 25–34.
   Google Scholar
• Yao L, Sgadari C, Furuke K et al, Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1999) 93: 1612–21.
   Google Scholar
• Terabe M, Matsui S, Noben-Trauth N et al, NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 1: 515–20.
   Google Scholar
• Kakuta S, Tagawa Y, Shibata S et al, Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology (2002) 105: 92–100.
   Google Scholar
• Yim JH, Wu SJ, Lowney JK et al, Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-gamma. J Interferon Cytokine Res (1999) 19: 723–9.
   Google Scholar
• Arnould R, Dubois J, Abikhalil F et al, Comparison of two cytotoxicity assays — tetrazolium derivative reduction (MTT) and tritiated thymidine uptake — on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res (1990) 10: 145–54.
   Google Scholar
• Dias AAM, Goodman AR, Santos JL et al, TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J Leuk Biol (2001) 69: 928–36.
   Google Scholar
• Taniguchi T, Tanaka N, Taki S, Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1. Eur Cytokine Netw (1998) 9 (3 Suppl): 43–8.
   Google Scholar
• Romeo G, Fiorucci G, Chiantore MV et al, IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res (2002) 22: 39–47.
   Google Scholar
• Huang S, Hendriks W, Althage A et al, Immune response in mice that lack the interferon-gamma receptor. Science (1993) 259: 1742–5.
   Google Scholar
• Cui J, Shin T, Kawano T et al, Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science (1997) 278: 1623–6.
   Google Scholar
• Garbe C, Krasagakis K, Effects of interferons and cytokines on melanoma cells. J Invest Dermatol (1993) 100(2 Suppl): 239S–44S.
   Google Scholar
• Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE, Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res (1995) 139: 169–82.
   Google Scholar
• Harvat BL, Seth P, Jetten AM, The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene (1997) 14: 2111–22.
   Google Scholar
• Harvat BL, Jetten AM, Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ (1996) 7: 289–300.
   Google Scholar
• Bromberg JF, Horvath CM, Wen Z et al, Transcriptionally active Stat1 is required for the anti-proliferative effects of both interferon-α and interferon-γ. Proc Nat Acad Sci USA (1996) 93: 7673–8.
   Google Scholar
• Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R, Interferon induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene (1998) 16: 217–25.
   Google Scholar
• Ikeda H, Old LJ, Schreiber RD, The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Fact Rev (2002) 13: 95–109.
   Google Scholar
• Chin YE, Kitagawa M, Kuida K et al, Activation of STAT signaling pathway can cause expression of caspase-1 and apoptosis. Mol Cell Biol (1997) 17: 5328–37.
   Google Scholar
• Detjen KM, Farwig K, Welzel M et al, Interferon-γ inhibits growth of human pancreatic carcinoma cells via caspase-1 depedent induction of apoptosis. Gut (2001) 49: 251–62.
   Google Scholar
• Xu X, Fu XY, Plate J, Chong AS, IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res (1998) 58: 2832–7.
   Google Scholar
• Konan KV, Taylor MW, Treatment of ME180 cells with interferongamma causes apoptosis as a result of tryptophan starvation. J Interferon Cytokine Res (1996) 16: 751–6.
   Google Scholar
• Ozaki Y, Edelstein MP, Duch DS, Induction of indoleamine 2, 3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Nat Acad Sci USA (1988) 85: 1242–6.
   Google Scholar
• Garecitano J, Perle MA, Vilcek J, Transcriptional basis for the differences in inducible nitric oxide synthase (iNOS) expression between nonmetastatic and metastatic murine melanoma cell lines. J Interferon Cytokine Res (1999) 19: 393–405.
   Google Scholar
• Dong Z, Staroselsky AH, Qi X et al, Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res (1994) 54: 789–93.
   Google Scholar
• Xie K, Dong Z, Fidler IJ, Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol (1996) 59: 797–803.
   Google Scholar
• Kaplan DH, Shankaran V, Dighe AS et al, Demonstration of an interferon-γ dependent tumor surveillance system in immunocompetent mice. Proc Nat Acad Sci USA (1998) 95: 7556–61.
   Google Scholar